Argus raised the firm’s price target on Boston Scientific (BSX) to $130 from $105 and keeps a Buy rating on the shares. The firm sees strong ...

So far, BSX stock has risen 19% year-to-date. Separately, CROX reports earnings tomorrow. Will the stock pop on the news? See ...

FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.

Edward J. Ludwig, a director at Boston Scientific Corp (NYSE:BSX), recently sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission ...

West Pharmaceutical's overall top line in the fourth quarter of 2024 continues to benefit from revenue growth in its Proprietary Products ... Celestica and Boston Scientific have been highlighted ...